TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today   SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the first quarter ended March 31, 2024. The Company will p

SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company's Chief Medical Officer and resident Key Opinion Leader, will review a selection of slides and discuss the clinical strategy for advancing the Company's lead asset tuspetinib (TUS) in a TUS+VEN+HMA triplet drug combination for the frontline treatmen

SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast:  Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BIe69f08fc83634a6aa38bf7081d82c6a2)   *Analysts interested in participating in the question-and-answer sess

Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance MechanismsTUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN Overall Response Rate of 48% in Heavily Pre-Treated Relapsed/Refractory AML Patients Tuspetinib Favorable Safety Profile Continues with TUS/VEN Doublet TherapyConference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today a

SAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast:    Date: Thursday, November 9, 2023 Time:  5:00 PM ETAudio Webcast Only: linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BIb770b610b0744016870ec2150989ea78)  *Analysts interested in participating in the question-and-answer sessi

            ─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67% in Patients with Mutated FLT3 ─ ─ Data Guide to Accelerated Approval Path for TUS/VEN Doublet in Patients Who Failed Prior Venetoclax, Including FLT3 Mutated and Wildtype ─ ─ Hanmi Pharmaceutical Commits Investment in Aptose Up to 19.99% Ownership or $7 Million ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company de

SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Thursday, August 10, 2023Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:link(https://register.vevent.com/register/BI29f5f8f4655b45cf8b92fd8f79f69f8f) *Analysts interested in participating in the question-and-answer session will pre-reg

─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet of Tuspetinib and Venetoclax Dosing Underway for Relapsed/Refractory AML Patients in APTIVATE Expansion Trial ─ ─ Brisk Enrollment of Tuspetinib Monotherapy and Doublet Arms in APTIVATE Expansion Trial; Early Clinical Activity Already Noted ─ ─ Tuspetinib Superior Safety Profile Continues ─ ─ Luxeptinib G3 Formulation Continuous Dosing is Ongoing ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, May 08, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose"

SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Monday, May 8, 2023Time:5:00 PM ETAudio Webcast Only:linkQ&A Participant Registration Link*:here(https://register.vevent.com/register/BI0c4e6d84e0b848f79be80dfa78e465bd) *Analysts interested in participating in the question-and-answer session will pre-register for

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continuous Dosing of G3 Formulation of Luxeptinib Ongoing ─ ─ Conference Call and Webcast at 5:00 pm ET Today ─ SAN DIEGO and TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced financial results for the fourth quarter and year ended Dece

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, including TP53-mutated/CK AML and FLT3-wildtype AML patients SAN DIEGO and TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS, OTC:APTOF), a clinical-stage precision oncology company, today reported updated and new data from Aptose's Phase 1/2 TUSCANY trial in newly diagnosed acute myeloid leukemia (AML) patients dosed with a 40 mg or 80 mg dose of tuspe

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public accounting firm of the Company (the "KPMG"), informed the Company that it will not stand for re-appointment for the Company's 2025 annual audit. The Company anticipates that KPMG will continue to review its quarterly interim financial results through the first two fiscal quarters of 2025. The Company

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025. Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with Aptose please contact your conference repre

SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Nasdaq Hearings Panel (the "Panel") has determined to delist the common shares of the Company from The Nasdaq Stock Market ("Nasdaq" or the "Exchange"). Under the terms of the Panel's December 17, 2024, decision in this matter (the "Decision"), the Company was required to demonstrate compliance with the Exchange's equity requirement in Listing Rule 5550(b)(1

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the year ended December 31, 2024, and provided a corporate update.   "During 2024 and into 20

SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it is in compliance with Nasdaq's minimum bid price requirement. On March 14, 2025, Nasdaq confirmed that, for ten consecutive business days, the closing bid price of the Company's common shares has been $1.00 p

TUS+VEN+AZA triplet achieves complete responses (CRs) in difficult-to-treat TP53-mutated/CK AML and FLT3-wildtype AML patients, including a measurable residual disease (MRD) negative remission Dosing of initial 40 mg cohort complete; no prolonged myelosuppression or dose-limiting toxicitiesNo dose reductions to the standard-of-care components of the regimen (AZA/VEN) in first cohortCSRC endorses escalation to 80 mg dosing, enrollment is open SAN DIEGO and TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to tre

SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that its board of directors (the "Board") has approved, subject to required regulatory and stock exchange approvals, a plan to consolidate all of its outstanding common shares (the "Common Shares") on the basis of 1 Common Share for every 30 Common Shares currently outstanding (the "Reverse Share Split"). The Company expects the Reverse Share Split to restore compliance with the minimum bid

SAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced it has entered into a common share purchase agreement and registration rights agreement with an institutional investor. The Committed Equity Facility agreement provides Aptose the right, in its sole option and discretion without obligation, to sell and issue up to $25 million of its common shares (the "Common Shares") over the course of 24 months to the Investor, subject to certain con

TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AMLTUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patientsTUS+VEN+AZA triplet shows favorable safety with no alteration of VEN and AZA dosingPK levels of TUS in the triplet remain equivalent to levels as TUS or TUS+VEN therapy SAN DIEGO and TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company, today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose's Phase 1/2 TUSCANY trial with a 40 mg dose of

HC Wainwright & Co. reiterated coverage of Aptose Biosciences with a rating of Buy and set a new price target of $12.00 from $14.00 previously

HC Wainwright & Co. reiterated coverage of Aptose Biosciences with a rating of Buy and set a new price target of $14.00 from $9.00 previously

Oppenheimer reiterated coverage of Aptose Biosciences with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

Jonestrading initiated coverage of Aptose Biosciences with a rating of Buy and set a new price target of $14.00

Jonestrading initiated coverage of Aptose Biosciences with a rating of Buy

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

3 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

4 - Aptose Biosciences Inc. (0000882361) (Issuer)

NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Greg Chow as Chief Financial and Business Officer (CFBO), effective immediately. Greg is an experienced executive with over 25 years of corporate finance, capital markets, investment banking, financial accounting, drug development operations, and business development experience. Over th

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the "Meeting"). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Company entitled to be voted, were represented by shareholders present or represented by proxy at the Meeting. The Company is pleased to announce that all of the nominees listed in the proxy

SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer. With a healthcare tenure of more than 25 years, Mr. Payne has held several CFO and senior management positions at biotech companies in addition to finance and accounting roles, and has overseen legal, corporate development and licensing functions. During his career, he has execu

SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that, at the Company's annual and special meeting of shareholders held today, May 23, 2023 (the "Meeting"), the proposed reverse stock split (the "Reverse Stock Split") of the Company's common shares (the "Common Shares"), as described in the proxy statement dated April 18, 2023 (the "Proxy Statement"), was approved by 93.44% of the votes cast at the Meeting. The Company also announced today that the board of dire

SAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Bernd R. Seizinger, M.D., Ph.D., to the Board of Directors, effective immediately. Aptose's Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Dr. Seizinger is an accomplished executive leader with more than 25 years of industry experience in both U.S. and European biotechnology and pharmaceutic

SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the position of Senior Vice President, Chief Financial Officer (CFO). In this role, Mr. Payne will lead Aptose's financial operations and serve as a member of the Company's executive management team. "As a highly accomplished CFO, Fletcher brings to Aptose extensive experience in corporate finance, strategy and operations within the biotechnology industry, including the

SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, May 31, 2022 (the "Meeting"). A total of 53.46% of the common shares of the Company entitled to be voted were represented by shareholders present or represented by proxy at the Meeting. The Company is pleased to announce that all of the nominees listed in the proxy statement dated April 19, 2022 were elected as

─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Philippe Ledru to the position of Chief Commercial Officer. In this role, Mr. Ledru is responsible for providing executive leadership and vision for commercial development and marketing strategies for the future commercial launches of Aptose's innovative oncology medicine

Janet Clennett, CPA, appointed Vice President, Finance Roger Davies, B.Sc., M. Phil, joins as Vice President, Operations SAN DIEGO and TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the appointment of two key members to its management team to support the company's finance and operations functions: Janet Clennett, CPA, has been named to Vice President, Finance; and Roger Davies, B.Sc., M. Phil, joins Aptose as Vice President, Operations. Janet Clennett has been named to the role of Vice President, Finance at Ap

SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 1, 2021 (the "Meeting"). A total of 72.83% of the issued and outstanding common shares of the Company were represented by shareholders present or represented by proxy at the Meeting. The Company is pleased to announce that all of the nominees listed in the proxy statement dated April 20, 2021 were elected as Directors. The resul